LINDA BOXER

Summary

Affiliation: Stanford University
Country: USA

Publications

  1. pmc The immunoglobulin heavy chain gene 3' enhancers induce Bcl2 deregulation and lymphomagenesis in murine B cells
    H Xiang
    Center for Molecular Biology in Medicine, Veterans Affairs Palo Alto Health Care System, Palo Alto, CA 94305 5156, USA
    Leukemia 25:1484-93. 2011
  2. ncbi request reprint Gene expression patterns associated with recurrent chromosomal translocations in acute lymphoblastic leukemia
    Bernard M Fine
    Division of Hematology, 269 Campus Dr, CCSR 1155, Stanford University School of Medicine, Stanford, CA 94305 5156, USA
    Blood 103:1043-9. 2004
  3. ncbi request reprint A Myc-associated zinc finger protein-related factor binding site is required for the deregulation of c-myc expression by the immunoglobulin heavy chain gene enhancers in Burkitt's lymphoma
    Hsien Ming Hu
    Center for Molecular Biology in Medicine, Veterans Affairs Palo Alto Health Care System, Stanford University School of Medicine, Stanford, California 94305, USA
    J Biol Chem 277:9819-24. 2002
  4. ncbi request reprint Allele-specific analysis of transcription factors binding to promoter regions
    Caroline A Heckman
    Center for Molecular Biology in Medicine, Veterans Affairs Palo Alto Health Care System and the Department of Medicine, Stanford University School of Medicine, CA 94305, USA
    Methods 26:19-26. 2002
  5. ncbi request reprint Critical elements of the immunoglobulin heavy chain gene enhancers for deregulated expression of bcl-2
    Caroline A Heckman
    Department of Medicine, Stanford University School of Medicine, Stanford, California 94305, USA
    Cancer Res 63:6666-73. 2003
  6. pmc Role of the cyclic AMP response element in the bcl-2 promoter in the regulation of endogenous Bcl-2 expression and apoptosis in murine B cells
    Hong Xiang
    Center for Molecular Biology in Medicine, Veterans Affairs Palo Alto Health Care System, and Department of Medicine, Stanford University School of Medicine, Stanford, CA 94305 5156, USA
    Mol Cell Biol 26:8599-606. 2006
  7. ncbi request reprint Impaired proliferation and survival of activated B cells in transgenic mice that express a dominant-negative cAMP-response element-binding protein transcription factor in B cells
    Chun yi Zhang
    Center for Molecular Biology in Medicine, Veterans Affairs Palo Alto Health Care System, California 94305, USA
    J Biol Chem 277:48359-65. 2002
  8. pmc Protein/DNA arrays identify nitric oxide-regulated cis-element and trans-factor activities some of which govern neuroblastoma cell viability
    Saravanakumar Dhakshinamoorthy
    Cell Death and Human Diseases Group, Division of Genomics and Genetics, Institute of Molecular and Cell Biology, Proteos, 61 Biopolis Drive, Singapore 138673, Republic of Singapore
    Nucleic Acids Res 35:5439-51. 2007
  9. ncbi request reprint Artificial zinc(II) complexes regulate cell cycle and apoptosis-related genes in tumor cell lines
    Jian Gao
    Department of Chemistry, Texas A and M University, College Station, Texas 77843 3255, USA
    Chembiochem 8:332-40. 2007
  10. pmc Histone deacetylase inhibitors down-regulate bcl-2 expression and induce apoptosis in t(14;18) lymphomas
    Hong Duan
    Center for Molecular Biology in Medicine, Veterans Affairs, Palo Alto Health Care System, Palo Alto, CA, USA
    Mol Cell Biol 25:1608-19. 2005

Research Grants

Collaborators

  • J Wang
  • G J L Kaspers
  • Lei M Li
  • Jian Gao
  • Caroline A Heckman
  • Bernard M Fine
  • Hong Duan
  • H Xiang
  • Chun yi Zhang
  • Saravanakumar Dhakshinamoorthy
  • Hong Xiang
  • Minh Ho
  • Harsimran S Saini
  • John W Mehew
  • Hsien Ming Hu
  • S Michie
  • L Ma
  • E J Noonan
  • H Duan
  • Poh Yong Ng
  • Shiva Ranjani Sridharan
  • Alan G Porter
  • Anne H Loonen
  • Carmen Sato-Bigbee
  • Karen M Gorse
  • Jochen Harbott
  • Martin Schrappe
  • Martin Stanulla
  • Susanne Viehmann
  • Thai Cao
  • Melissa A Wheeler
  • Lina Somsouk
  • Magdalena Arcinas
  • Yu Ling Wu

Detail Information

Publications14

  1. pmc The immunoglobulin heavy chain gene 3' enhancers induce Bcl2 deregulation and lymphomagenesis in murine B cells
    H Xiang
    Center for Molecular Biology in Medicine, Veterans Affairs Palo Alto Health Care System, Palo Alto, CA 94305 5156, USA
    Leukemia 25:1484-93. 2011
    ..The IgH-3'E-bcl2 mice developed monoclonal B-cell follicular lymphomas, which were slowly progressive. These studies show that the Igh 3' enhancers have an important role in the deregulation of Bcl2 and B-cell lymphomagenesis in vivo...
  2. ncbi request reprint Gene expression patterns associated with recurrent chromosomal translocations in acute lymphoblastic leukemia
    Bernard M Fine
    Division of Hematology, 269 Campus Dr, CCSR 1155, Stanford University School of Medicine, Stanford, CA 94305 5156, USA
    Blood 103:1043-9. 2004
    ..Notably, we found that the erythropoietin receptor (EPOR) is consistently highly expressed in TEL/AML1 ALL compared with BCR/ABL or MLL...
  3. ncbi request reprint A Myc-associated zinc finger protein-related factor binding site is required for the deregulation of c-myc expression by the immunoglobulin heavy chain gene enhancers in Burkitt's lymphoma
    Hsien Ming Hu
    Center for Molecular Biology in Medicine, Veterans Affairs Palo Alto Health Care System, Stanford University School of Medicine, Stanford, California 94305, USA
    J Biol Chem 277:9819-24. 2002
    ..Taken together, these findings suggest that this regulatory element is required for the full activation of c-myc promoter activity by the immunoglobulin heavy chain gene enhancer...
  4. ncbi request reprint Allele-specific analysis of transcription factors binding to promoter regions
    Caroline A Heckman
    Center for Molecular Biology in Medicine, Veterans Affairs Palo Alto Health Care System and the Department of Medicine, Stanford University School of Medicine, CA 94305, USA
    Methods 26:19-26. 2002
    ..A detailed description of this methodology with examples from our studies are provided with a discussion of how these techniques may be applied to the study of other genes...
  5. ncbi request reprint Critical elements of the immunoglobulin heavy chain gene enhancers for deregulated expression of bcl-2
    Caroline A Heckman
    Department of Medicine, Stanford University School of Medicine, Stanford, California 94305, USA
    Cancer Res 63:6666-73. 2003
    ..These results suggest that the interactions of the nuclear factor kappaB and Sp1 transcription factors with the immunoglobulin heavy chain enhancer region are important for bcl-2 deregulation in t(14;18) cells...
  6. pmc Role of the cyclic AMP response element in the bcl-2 promoter in the regulation of endogenous Bcl-2 expression and apoptosis in murine B cells
    Hong Xiang
    Center for Molecular Biology in Medicine, Veterans Affairs Palo Alto Health Care System, and Department of Medicine, Stanford University School of Medicine, Stanford, CA 94305 5156, USA
    Mol Cell Biol 26:8599-606. 2006
    ..Our findings indicate that the CRE in the bcl-2 promoter has an important functional role in the regulation of endogenous Bcl-2 expression and plays a critical role in the coordination of signals that regulate B-cell survival...
  7. ncbi request reprint Impaired proliferation and survival of activated B cells in transgenic mice that express a dominant-negative cAMP-response element-binding protein transcription factor in B cells
    Chun yi Zhang
    Center for Molecular Biology in Medicine, Veterans Affairs Palo Alto Health Care System, California 94305, USA
    J Biol Chem 277:48359-65. 2002
    ..These studies demonstrate that B-cell activation requires phosphorylation of CREB for the proliferative response and to protect against activation-induced apoptosis...
  8. pmc Protein/DNA arrays identify nitric oxide-regulated cis-element and trans-factor activities some of which govern neuroblastoma cell viability
    Saravanakumar Dhakshinamoorthy
    Cell Death and Human Diseases Group, Division of Genomics and Genetics, Institute of Molecular and Cell Biology, Proteos, 61 Biopolis Drive, Singapore 138673, Republic of Singapore
    Nucleic Acids Res 35:5439-51. 2007
    ..Our results emphasize that a DNA/protein array approach can reveal novel, global transcription factor activities stimulated by cell death-regulating molecules...
  9. ncbi request reprint Artificial zinc(II) complexes regulate cell cycle and apoptosis-related genes in tumor cell lines
    Jian Gao
    Department of Chemistry, Texas A and M University, College Station, Texas 77843 3255, USA
    Chembiochem 8:332-40. 2007
    ..This study provides a new insight into the development of zinc(II) complexes as potential drugs...
  10. pmc Histone deacetylase inhibitors down-regulate bcl-2 expression and induce apoptosis in t(14;18) lymphomas
    Hong Duan
    Center for Molecular Biology in Medicine, Veterans Affairs, Palo Alto Health Care System, Palo Alto, CA, USA
    Mol Cell Biol 25:1608-19. 2005
    ..Mutation of Sp1 and C/EBPalpha binding sites reduced the TSA-induced repression of bcl-2 promoter activity. This study provides a mechanistic rationale for the use of HDAC inhibitors in the treatment of human t(14;18) lymphomas...
  11. ncbi request reprint A genome-wide view of the in vitro response to l-asparaginase in acute lymphoblastic leukemia
    Bernard M Fine
    Center for Molecular Biology in Medicine, Veterans Affairs Palo Alto Health Care System and Department of Medicine, Palo Alto, CA, USA
    Cancer Res 65:291-9. 2005
    ..These results suggest that targeting particular genes involved in the response to amino acid starvation in ALL cells may provide a novel way to overcome l-asparaginase resistance...
  12. ncbi request reprint NF-kappaB activates Bcl-2 expression in t(14;18) lymphoma cells
    Caroline A Heckman
    Center for Molecular Biology in Medicine, Veterans Affairs Palo Alto Health Care System, Palo Alto, CA 94305, USA
    Oncogene 21:3898-908. 2002
    ..We therefore conclude that the activation of bcl-2 by NF-kappaB in t(14;18) lymphoma cells is mediated through the CRE and Sp1 binding sites...
  13. ncbi request reprint Regulation of Bcl-2 expression by C/EBP in t(14;18) lymphoma cells
    Caroline A Heckman
    Center for Molecular Biology in Medicine, Veterans Affairs Palo Alto Health Care System, Palo Alto, CA 94304, USA
    Oncogene 22:7891-9. 2003
    ..We conclude that C/EBPalpha and C/EBPbeta contribute to the deregulated expression of Bcl-2 in t(14;18) lymphoma cells...
  14. ncbi request reprint Neurotrophin-3 and a CREB-mediated signaling pathway regulate Bcl-2 expression in oligodendrocyte progenitor cells
    Harsimran S Saini
    Department of Biochemistry, Virginia Commonwealth University School of Medicine, Richmond, Virginia 23298, USA
    J Neurochem 89:951-61. 2004
    ..Together with our previous results, these observations suggest that CREB may play an important role in linking proliferation and survival pathways in the OLG progenitors...

Research Grants33

  1. ACTIVATION OF BCL-2 IN HEMATOLOGIC MALIGNANCIES
    Linda M Boxer; Fiscal Year: 2010
    ..These studies will provide new information that can be used to treat the disease in humans. ..
  2. Molecular Studies of Human All
    LINDA BOXER; Fiscal Year: 2003
    ..Determination of changes in gene expression in ALL cells, both sensitive and resistant, in response to chemotherapeutic agents. 4. Identification of fusion protein-specific events and studies of important genes and pathways in cell line ..
  3. ACTIVATION OF BCL-2 IN HEMATOLOGIC MALIGNANCIES
    LINDA BOXER; Fiscal Year: 2003
    ..These studies should provide the groundwork for the development of novel therapies for future therapeutic trials in lymphomas with deregulated bcl-2 expression. ..
  4. CONTROL OF C-MYC TRANSCRIPTION IN HIGH GRADE LYMPHOMA
    LINDA BOXER; Fiscal Year: 2003
    ..5.Development of strategies to interfere with c-myc transcription that is driven by the IgH enhancers. We have shown that several NF-kB sites are critical for deregulated c-myc expression, and we will first target the function of NF-kB. ..
  5. CONTROL OF C-MYC TRANSCRIPTION IN HIGH GRADE LYMPHOMA
    LINDA BOXER; Fiscal Year: 2004
    ..5.Development of strategies to interfere with c-myc transcription that is driven by the IgH enhancers. We have shown that several NF-kB sites are critical for deregulated c-myc expression, and we will first target the function of NF-kB. ..
  6. Molecular Studies of Human All
    LINDA BOXER; Fiscal Year: 2004
    ..Determination of changes in gene expression in ALL cells, both sensitive and resistant, in response to chemotherapeutic agents. 4. Identification of fusion protein-specific events and studies of important genes and pathways in cell line ..
  7. ACTIVATION OF BCL-2 IN HEMATOLOGIC MALIGNANCIES
    LINDA BOXER; Fiscal Year: 2004
    ..These studies should provide the groundwork for the development of novel therapies for future therapeutic trials in lymphomas with deregulated bcl-2 expression. ..
  8. CONTROL OF C-MYC TRANSCRIPTION IN HIGH GRADE LYMPHOMA
    LINDA BOXER; Fiscal Year: 2005
    ..5.Development of strategies to interfere with c-myc transcription that is driven by the IgH enhancers. We have shown that several NF-kB sites are critical for deregulated c-myc expression, and we will first target the function of NF-kB. ..
  9. ACTIVATION OF BCL-2 IN HEMATOLOGIC MALIGNANCIES
    LINDA BOXER; Fiscal Year: 2005
    ..These studies should provide the groundwork for the development of novel therapies for future therapeutic trials in lymphomas with deregulated bcl-2 expression. ..
  10. ACTIVATION OF BCL-2 IN HEMATOLOGIC MALIGNANCIES
    LINDA BOXER; Fiscal Year: 2006
    ..These studies should provide the groundwork for the development of novel therapies for future therapeutic trials in lymphomas with deregulated bcl-2 expression. ..
  11. TRAINING PROGRAM IN INVESTIGATIVE HEMATOLOGY
    LINDA BOXER; Fiscal Year: 2007
    ..At the conclusion of their training, trainees will be prepared for a career in academic hematology, as an independent investigator at the forefront of science and hematology. (End of Abstract) ..
  12. Activation of BCL-2 in Hematologic Malgnancies
    LINDA BOXER; Fiscal Year: 2007
    ..These studies will provide new information that can be used to treat the disease in humans. ..
  13. ACTIVATION OF BCL-2 IN HEMATOLOGIC MALIGNANCIES
    LINDA BOXER; Fiscal Year: 2009
    ..These studies will provide new information that can be used to treat the disease in humans. ..
  14. ACTIVATION OF BCL-2 IN HEMATOLOGIC MALIGNANCIES
    LINDA BOXER; Fiscal Year: 2002
    ..These studies should provide the groundwork for the development of novel therapies for future therapeutic trials in lymphomas with deregulated bcl-2 expression. ..
  15. Molecular Studies of Human All
    LINDA BOXER; Fiscal Year: 2002
    ..Determination of changes in gene expression in ALL cells, both sensitive and resistant, in response to chemotherapeutic agents. 4. Identification of fusion protein-specific events and studies of important genes and pathways in cell line ..
  16. CONTROL OF C-MYC TRANSCRIPTION IN HIGH GRADE LYMPHOMA
    LINDA BOXER; Fiscal Year: 2002
    ..5.Development of strategies to interfere with c-myc transcription that is driven by the IgH enhancers. We have shown that several NF-kB sites are critical for deregulated c-myc expression, and we will first target the function of NF-kB. ..
  17. ACTIVATION OF BCL 2 IN HEMATOLOGIC MALIGNANCIES
    LINDA BOXER; Fiscal Year: 1999
    ..The transcription factors that are required for the activation of expression of BCL-2 will be identified, and the region of the immunoglobulin locus that are responsible for this will be characterized. ..
  18. CONTROL OF C MYC TRANSCRIPTION IN HIGH GRADE LYMPHOMAS
    LINDA BOXER; Fiscal Year: 1999
    ..The transcription factors that are required for the activation of c-myc will be identified and the regions of the immunoglobulin locus which are responsible for this will be defined. ..
  19. ACTIVATION OF BCL-2 IN HEMATOLOGIC MALIGNANCIES
    LINDA BOXER; Fiscal Year: 1993
    ..A model system will be used to determine whether the results of the in vivo studies can be reproduced in a system that leads to bcl-2 deregulation; this will also be used to determine which elements are required for deregulation...
  20. ACTIVATION OF BCL 2 IN HEMATOLOGIC MALIGNANCIES
    LINDA BOXER; Fiscal Year: 2000
    ..The transcription factors that are required for the activation of expression of BCL-2 will be identified, and the region of the immunoglobulin locus that are responsible for this will be characterized. ..
  21. CONTROL OF C MYC TRANSCRIPTION IN HIGH GRADE LYMPHOMAS
    LINDA BOXER; Fiscal Year: 2000
    ..The transcription factors that are required for the activation of c-myc will be identified and the regions of the immunoglobulin locus which are responsible for this will be defined. ..
  22. CONTROL OF MYC TRANSCRIPTION IN HIGH GRADE LYMPHOMA
    LINDA BOXER; Fiscal Year: 2001
    ..5.Development of strategies to interfere with c-myc transcription that is driven by the IgH enhancers. We have shown that several NF-kB sites are critical for deregulated c-myc expression, and we will first target the function of NF-kB. ..
  23. ACTIVATION OF BCL 2 IN HEMATOLOGIC MALIGNANCIES
    LINDA BOXER; Fiscal Year: 2001
    ..The transcription factors that are required for the activation of expression of BCL-2 will be identified, and the region of the immunoglobulin locus that are responsible for this will be characterized. ..
  24. Molecular Studies of Human All
    LINDA BOXER; Fiscal Year: 2001
    ..Determination of changes in gene expression in ALL cells, both sensitive and resistant, in response to chemotherapeutic agents. 4. Identification of fusion protein-specific events and studies of important genes and pathways in cell line ..